Clinical Trials Browser

Phase 3 × Active not recruiting × pegylated granulocyte colony-stimulating factor × Clear all

NCT03907488 2026-06-01

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Phase 3 Active not recruiting

994 enrolled 11 charts 1 FDA

Hodgkin Disease